(Q38487058)

3 September 2017

Relating statin therapy to C-reactive protein levels (English)

1 reference

3 September 2017

1 reference

Sheila A Doggrell

1

1 reference

PubMed ID

16086647

3 September 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Pharmacotherapy

3 September 2017

1 reference

3 September 2017

6

1 reference

3 September 2017

9

1 reference

3 September 2017

1597-1600

1 reference

Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role

3 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

Reduction in C-reactive protein through cardiac rehabilitation and exercise training

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1597

10.1517/14656566.6.9.1597

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

16086647